The world’s most valuable company crammed a lot into the tablespoon-sized volume of an Apple Watch. There’s GPS, a heart-rate sensor, cellular connectivity, and computing resources that not long ago would have filled a desk-dwelling beige box. The wonder gadget doesn’t have a sphygmomanometer for measuring blood pressure or polysomnographic equipment found in a sleep lab—but thanks to machine learning, it might be able to help with their work.
Immunotherapy for leukemia patients has been nothing short of a miracle. Now scientists hope to use that science and other forms of gene therapy to tackle three of the deadliest forms of cancer: glioblastoma (brain cancer), sarcoma (bone cancer) and ovarian cancer. Three scientists have received $1.3 million in critical funding from the Alliance for Cancer Gene Therapy (ACGT), the nation's only nonprofit dedicated exclusively to cell and gene therapies for cancer.
The major advance in this study is “their methodology for designing simple DNA devices that work in parallel to solve nontrivial tasks,” notes Duke University computer scientist John H. Reif in an article in the same issue of Science. Such tasks could include synthesizing a drug in a molecular factory or delivering a drug only when a specific signal is present in bloodstreams, say the researchers. “So far, the development of DNA robots has been limited to simple functions,” the researchers note.
While the status of the U.S. health-care system has divided Congress, there’s one reform provision that unites a bipartisan majority of lawmakers, including Sens. Bob Casey and Pat Toomey: Repealing the innovation-crushing medical device excise tax.
The FDA said Wednesday it approved Novartis AG's Kymriah for certain children and young adults who suffer from a form of leukemia. "We're entering a new frontier in medical innovation with the ability to reprogram a patient's own cells to attack a deadly cancer," FDA Commissioner Scott Gottlieb said.
A radical new electronic skin monitor developed by Korean and U.S. scientists tracks heart rate, respiration, muscle movement, acceleration, and electrical activity in the heart, muscles, eyes, and brain and wirelessly transmits it to a smartphone, allowing for continuous health monitoring.
Color Genomics, a start-up that sells genetic tests to assess cancer and other health risks, just raised an additional $80 million from a slew of high-profile investors. That brings its total financing to $150 million, making it one of the most well-funded health-technology companies in Silicon Valley.
Research done by the Georgetown’s Center on Education and the Workforce predicts that there will be 9 million STEM jobs by 2018. This is a list of coolest occupations in STEM right now across three promising industries, offering incredible prospects for growth, impact and compensation.
Imagine replacing a damaged eye with a window directly into the brain -- one that communicates with the visual part of the cerebral cortex by reading from a million individual neurons and simultaneously stimulating 1,000 of them with single-cell accuracy, allowing someone to see again.
Goldman Sachs Group Inc. economists say America’s opioid epidemic is probably sidelining people in their prime working years and contributing to the stubbornly low rate of men and women who are either employed or looking for jobs. “Use of both legal prescription pain relievers and illegal drugs is part of the story of declining prime-age participation, especially for men,” Goldman economists wrote in the study released Wednesday.